Healthcare Industry News: chronic sinusitis
News Release - November 7, 2006
Naryx Pharma, Inc. Announces the Election of Geron Corporation Executive Alan B. Colowick to its Board of DirectorsSANTA BARBARA, Calif.--(HSMN NewsFeed)--Naryx Pharma, Inc., a leader in the development of new therapies for patients with chronic sinusitis, announced today that Alan B. Colowick, M.D., M.P.H., has been elected to its Board of Directors.
"We are thrilled that Alan has agreed to join our board," said Michael Narachi, Chairman of the Board. "Alan has a broad background in all aspects of product development, registration, and commercialization, and we know that this experience will be a key resource as we continue to develop new therapies for chronic sinusitis."
About Naryx Pharma
Naryx(TM) is a privately-held company dedicated to developing innovative therapies for chronic sinusitis, based on advances in the targeted delivery of medications. chronic sinusitis is a disease that afflicts up to 30 million people in the U.S. alone. The Company will focus on obtaining marketing approvals for its promising intellectual property portfolio of intranasal drug formulations.
Source: Naryx Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.